Editas Medicine

Editas Medicine is a transformative genome editing company which is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2013
Size (employees)
89 (est)
Editas Medicine was founded in 2013 and is headquartered in Cambridge, US

Key People/Management at Editas Medicine

Katrine Bosley

Katrine Bosley

CEO
Andrew Hack

Andrew Hack

CFO
Gerald Cox

Gerald Cox

Chief Medical Officer
Charles Albright

Charles Albright

Chief Scientific Officer
Keith Joung

Keith Joung

Co - Founder

Editas Medicine Office Locations

Editas Medicine has an office in Cambridge
Cambridge, US (HQ)
11 Hurley St
Show all (1)

Editas Medicine Financials and Metrics

Editas Medicine Financials

USD

Net income (Q2, 2017)

(26.4 m)

EBIT (Q2, 2017)

(26.1 m)

Market capitalization (16-Feb-2018)

1.4 b

Cash (30-Jun-2017)

144.1 m

EV

1.3 b
Editas Medicine's current market capitalization is $1.4 b.
USDFY, 2016

R&D expense

57 m

General and administrative expense

46.3 m

Operating expense total

103.2 m

EBIT

(97.2 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

8.9 m10.4 m10.8 m19 m17.3 m

General and administrative expense

9.8 m12.2 m11.3 m12.3 m11.9 m

Operating expense total

18.6 m22.6 m22.1 m31.3 m29.2 m

EBIT

(17.8 m)(19.2 m)(21.2 m)(30.6 m)(26.1 m)
USDFY, 2016

Cash

185.3 m

Accounts Receivable

88 k

Inventories

1.8 m

Current Assets

187.2 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

229.2 m217.7 m199.9 m351.6 m144.1 m

Accounts Receivable

1.1 m1.2 m1.1 m945 k820 k

Current Assets

232.2 m221.2 m203.4 m353.8 m327.9 m

PP&E

15 m26.7 m37.1 m39.6 m39.4 m
USDFY, 2016

Net Income

(97.2 m)

Accounts Receivable

88 k

Inventories

1.8 m

Accounts Payable

4.6 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(17.7 m)(19 m)(21 m)(31.1 m)

Accounts Receivable

1.1 m1.2 m1.1 m945 k

Accounts Payable

2.9 m5.8 m3.7 m15.2 m
Y, 2017

EV/EBIT

-49.1 x

Financial Leverage

2 x
Show all financial metrics

Editas Medicine Operating Metrics

FY, 2016

Patents Pending

500

Patents Issued

41
Show all operating metrics

Editas Medicine Market Value History

Editas Medicine's Web-traffic and Trends

Editas Medicine Online and Social Media Presence

Editas Medicine Company Life and Culture

You may also be interested in